Medtronic Receives FDA Approval For New Single-Chamber ICDs That Detect Atrial Fibrillation
Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the Visia AF MRISureScanand Visia AFsingle-chamber implantable cardioverter defibrillators (ICDs). The Visia AF devices can detect previously undiagnosed and/or asymptomatic atrial fibrillation (AF) and monitor recurrent AF, while treating life-threatening rhythms in the lower chambers of the heart. The Visia AF ICD systems will be commercially available in early summer.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news
More News: Atrial Fibrillation | Cardiology | Food and Drug Administration (FDA) | Heart | Medical Devices